Stoneridge Investment Partners LLC cut its position in shares of Omeros Corporation (NASDAQ:OMER) by 37.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 123,901 shares of the biopharmaceutical company’s stock after selling 74,910 shares during the period. Stoneridge Investment Partners LLC owned about 0.32% of Omeros Corporation worth $1,303,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Group LTD raised its position in Omeros Corporation by 64.4% in the first quarter. BlackRock Group LTD now owns 12,080 shares of the biopharmaceutical company’s stock worth $186,000 after buying an additional 4,734 shares during the last quarter. BlackRock Fund Advisors raised its position in Omeros Corporation by 0.7% in the first quarter. BlackRock Fund Advisors now owns 1,471,968 shares of the biopharmaceutical company’s stock worth $22,580,000 after buying an additional 10,605 shares during the last quarter. UBS Group AG raised its position in Omeros Corporation by 0.8% in the first quarter. UBS Group AG now owns 333,744 shares of the biopharmaceutical company’s stock worth $5,120,000 after buying an additional 2,631 shares during the last quarter. Geode Capital Management LLC raised its position in Omeros Corporation by 7.6% in the first quarter. Geode Capital Management LLC now owns 244,865 shares of the biopharmaceutical company’s stock worth $3,756,000 after buying an additional 17,276 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in Omeros Corporation during the second quarter worth $17,641,000. Institutional investors and hedge funds own 47.99% of the company’s stock.

Shares of Omeros Corporation (NASDAQ:OMER) traded up 3.39% during mid-day trading on Thursday, reaching $11.90. The company’s stock had a trading volume of 217,831 shares. The stock’s market capitalization is $467.59 million. Omeros Corporation has a 12-month low of $8.90 and a 12-month high of $16.80. The company’s 50-day moving average price is $11.40 and its 200-day moving average price is $12.28.

Omeros Corporation (NASDAQ:OMER) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.18. The firm earned $10 million during the quarter, compared to the consensus estimate of $9.80 million. During the same period in the prior year, the company posted ($0.44) EPS. The firm’s revenue was up 212.5% compared to the same quarter last year. On average, equities research analysts forecast that Omeros Corporation will post ($1.55) earnings per share for the current fiscal year.

A number of research analysts have weighed in on OMER shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $21.00 target price on shares of Omeros Corporation in a report on Wednesday, August 10th. Maxim Group cut their price objective on Omeros Corporation from $30.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. WBB Securities reissued a “buy” rating and set a $75.00 price objective on shares of Omeros Corporation in a report on Tuesday, June 14th. Wedbush reissued an “outperform” rating and set a $56.00 price objective (down previously from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. Finally, FBR & Co reissued an “outperform” rating and set a $38.00 price objective on shares of Omeros Corporation in a report on Wednesday, June 29th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $35.86.

In other news, VP Marcia S. Kelbon sold 15,900 shares of the firm’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $11.56, for a total value of $183,804.00. Following the transaction, the vice president now owns 179,497 shares of the company’s stock, valued at $2,074,985.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Marcia S. Kelbon sold 16,000 shares of the firm’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the transaction, the vice president now directly owns 179,597 shares in the company, valued at approximately $1,959,403.27. The disclosure for this sale can be found here. 13.60% of the stock is owned by insiders.

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.